Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Caliway Biopharmaceuticals Co Ltd
Net Issuance of Debt
Caliway Biopharmaceuticals Co Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Net Issuance of Debt
-NT$8.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Issuance of Debt
-NT$133.7m
|
CAGR 3-Years
43%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Net Issuance of Debt
-NT$317.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Issuance of Debt
NT$75.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Issuance of Debt
NT$9.2B
|
CAGR 3-Years
58%
|
CAGR 5-Years
37%
|
CAGR 10-Years
36%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Issuance of Debt
NT$363.5m
|
CAGR 3-Years
53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Caliway Biopharmaceuticals Co Ltd
Glance View
Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
See Also
What is Caliway Biopharmaceuticals Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
-8.9m
TWD
Based on the financial report for Dec 31, 2025, Caliway Biopharmaceuticals Co Ltd's Net Issuance of Debt amounts to -8.9m TWD.
What is Caliway Biopharmaceuticals Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
19%
Over the last year, the Net Issuance of Debt growth was -3%. The average annual Net Issuance of Debt growth rates for Caliway Biopharmaceuticals Co Ltd have been 11% over the past three years , 19% over the past five years .
